Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine, paroxetine, and melatonin for insomnia during opioid withdrawal
IRCT20260806070551N1Phase 3Completed
- Sponsor
- Fasa University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirtazapine, paroxetine and melatonin in Insomnia (4 arms), sponsored by Fasa University of Medical Sciences. Primary endpoints: Most effective medication for insomnia during opioid withdrawal, Change in Pittsburgh Sleep Quality Index and 1 more. Started Aug 2026; status: completed.
02
Drugs
mirtazapineparoxetinemelatonin
03
Conditions
Insomnia
Beyond the preview
Go deeper on IRCT20260806070551N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260806070551N1.